Aclaris Therapeutics annual gross margin
2017
2018
2019
2020
2021
2022
2023
2024
2025
Aclaris Therapeutics Gross Margin Growth & History (ACRS)
Aclaris Therapeutics's gross margin was 73.28% for fiscal 2025.
View full Aclaris Therapeutics company overviewAclaris Therapeutics annual gross margin history
| Fiscal year | Period ended | Gross margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | 73.28% | −11.80 pp |
| 2024 | 2024-12-31 | 85.09% | −3.96 pp |
| 2023 | 2023-12-31 | 89.05% | +2.57 pp |
| 2022 | 2022-12-31 | 86.48% | +56.19 pp |
| 2021 | 2021-12-31 | 30.29% | +9.48 pp |
| 2020 | 2020-12-31 | 20.81% | +16.74 pp |
| 2019 | 2019-12-31 | 4.07% | −48.62 pp |
| 2018 | 2018-12-31 | 52.69% | +24.41 pp |
| 2017 | 2017-12-31 | 28.28% | — |
Aclaris Therapeutics quarterly gross margin
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Gross margin | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | 86.62% | +15.60 pp |
| Q1 2026 | 2026-03-31 | 80.21% | +14.99 pp |
| Q4 2025 | 2025-12-31 | 58.92% | −33.43 pp |
| Q3 2025 | 2025-09-30 | 83.69% | −1.26 pp |
| Q2 2025 | 2025-06-30 | 71.02% | −6.42 pp |
| Q1 2025 | 2025-03-31 | 65.22% | −1.04 pp |
| Q4 2024 | 2024-12-31 | 92.35% | −3.53 pp |
| Q3 2024 | 2024-09-30 | 84.95% | −5.91 pp |
| Q2 2024 | 2024-06-30 | 77.44% | +33.19 pp |
| Q1 2024 | 2024-03-31 | 66.26% | −1.77 pp |
| Q4 2023 | 2023-12-31 | 95.87% | +7.19 pp |
| Q3 2023 | 2023-09-30 | 90.86% | −4.28 pp |
| Q2 2023 | 2023-06-30 | 44.25% | +14.14 pp |
| Q1 2023 | 2023-03-31 | 68.04% | +47.53 pp |
| Q4 2022 | 2022-12-31 | 88.69% | +65.24 pp |
| Q3 2022 | 2022-09-30 | 95.15% | +61.39 pp |
| Q2 2022 | 2022-06-30 | 30.10% | −0.65 pp |
| Q1 2022 | 2022-03-31 | 20.51% | −11.85 pp |
| Q4 2021 | 2021-12-31 | 23.45% | +4.84 pp |
| Q3 2021 | 2021-09-30 | 33.76% | +15.81 pp |
| Q2 2021 | 2021-06-30 | 30.76% | −1.35 pp |
| Q1 2021 | 2021-03-31 | 32.36% | +22.55 pp |
| Q4 2020 | 2020-12-31 | 18.61% | +12.49 pp |
| Q3 2020 | 2020-09-30 | 17.94% | +1.97 pp |
| Q2 2020 | 2020-06-30 | 32.11% | +44.30 pp |
| Q1 2020 | 2020-03-31 | 9.81% | +5.37 pp |
| Q4 2019 | 2019-12-31 | 6.12% | +1.76 pp |
| Q3 2019 | 2019-09-30 | 15.97% | −22.94 pp |
| Q2 2019 | 2019-06-30 | −12.19% | −80.06 pp |
| Q1 2019 | 2019-03-31 | 4.43% | −9.07 pp |
| Q4 2018 | 2018-12-31 | 4.36% | −20.16 pp |
| Q3 2018 | 2018-09-30 | 38.91% | +5.14 pp |
| Q2 2018 | 2018-06-30 | 67.87% | — |
| Q1 2018 | 2018-03-31 | 13.51% | — |
| Q4 2017 | 2017-12-31 | 24.52% | — |
| Q3 2017 | 2017-09-30 | 33.77% | — |
Aclaris Therapeutics gross margin trends
Over the last five fiscal years, Aclaris Therapeutics's gross margin increased from 20.81% to 73.28%, a change of +52.47 percentage points. The latest reported quarter, Q2 2026, shows 86.62%.
About the metric
What gross margin means
Gross margin measures the percentage of revenue remaining after the direct costs of producing goods or services. It helps show how efficiently a company turns sales into gross profit before operating expenses.
Calculation and source
How gross margin is calculated
TickerStat calculates gross margin as SEC-reported gross profit divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Aclaris Therapeutics source filings ↗